Sponsors, grant funders & donors
A huge thank you to our sponsors, grant funders & donors for their invaluable support for RAREsummit23.
Thank you for partnering with us to improve the lives of those affected by rare conditions.
The NIHR BioResource is part of the National Institute for Health and Care Research (NIHR), who are England’s largest funder of health and care research. We are at the heart of efforts to improve healthcare and the long-term prevention and treatment of disease. The BioResource brings together researchers and willing volunteers to contribute to leading research that will benefit everyone. We collaborate with leading research groups in academia, NHS and industry to rapidly translate the findings in the lab into benefits for the clinic. Over 250,000 people, with and without health conditions, have signed up to volunteer with the BioResource.
LifeArc is a self-financing medical research charity. Our ambition is to transform the way diseases are identified and treated. Through our own work and in partnerships, we accelerate healthcare innovation by transforming promising life science ideas into life-changing medical breakthroughs for patients.
Alexion Astra Zeneca is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Their mission is to transform the lives of people living with rare conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services.
Healx is a mission-driven techbio company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. By combining frontier AI technology with deep drug discovery and development expertise, Healx accelerates the pace, increases the scale and improves the chance of success of rare disease treatment development to meet the huge unmet need and have unprecedented impact in the rare disease community.
Congenica Congenica is a digital health company providing innovative software and solutions for the analysis and interpretation of genomic data. It helps to reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide. Congenica is the exclusive Clinical Decision Support Partner for the National Health Service (NHS) Genomic Medicine Service and has a global footprint supporting leading international laboratories, academic medical centres, hospitals and biopharmaceutical companies. Congenica was founded 10 years ago, based on pioneering work at the Wellcome Trust Sanger Institute and UK NHS. Its products combine state-of-the-art technology, market-leading automation, machine learning and artificial intelligence to enable its uniquely differentiated platform to be employed in all areas of human disease where genomic information is key to unlock actionable insights. Congenica’s products and services are consolidated on one single scalable, automated analysis and diagnostic platform which has received the CE Mark under the In Vitro Diagnostics Directive for both Rare Diseases and Somatic and Inherited Oncology.
Bionical Emas is a global Contract Research Organization (CRO) combining Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) bringing life-changing medicines to patients around the world. Their unique integrated business model, with its range of services and capabilities, benefit many of the world’s leading pharma and biotech companies. This distinctive offering enables them to maximize access and evidence generation at every stage of the drug development pathway. Bionical Emas has a dedicated Rare Disease Team that consists of Global Patient Advocacy and Rare Disease Insights Specialists who drive their strong focus on patient centricity and customize clinical development and early access programs, to ensure they are carefully designed to meet the nuances and requirements that a rare disease can present.
Oxford Nanopore Technologies make a novel generation of DNA/RNA sequencing
technology that provides rich data, is fast, accessible and easy to use. Our goal is to
disrupt the way that biological analyses are currently performed, and open up new
applications that have a profound, positive impact on society.
The Evolution Education Trust fund the use of evolutionary science in research, interventions, education and outreach. The Trust has allocated over £24M since 2010 to projects that improve the public understanding of the Theory of Evolution and apply it to address major challenges in nature conservation and human health.